Literature DB >> 35018337

The etiology of SARS-CoV-.2 associated intra-cranial hemorrhage is broad.

Josef Finsterer1,2, Fulvio Alexandre Scorza2, Daniel Matovu2.   

Abstract

Entities:  

Keywords:  COVID-19; Central nervous system; Cerebral bleeding; SARS-CoV-2; Strokes

Year:  2022        PMID: 35018337      PMCID: PMC8731222          DOI: 10.1016/j.hest.2022.01.001

Source DB:  PubMed          Journal:  Brain Hemorrhages        ISSN: 2589-238X


× No keyword cloud information.

Letter to the Editor

With eagerly read the review article by Daly et al. about SARS-CoV-2 associated intra-cranial haemorrhage (ICH) (Daly et al., 2021). It was found that SARS-CoV-2 infections not only require treatment of acute respiratory distress syndrome (ARDS), vasculopathy, and coagulopathy, but also of neurological comorbidity, and that evidence-based treatments which reduce COVID-19 mortality may increase the risk of developing ICH (Daly et al., 2021). The study is appealing but raises concerns which require discussion. A pathophysiological mechanism explaining ICH in SARS-CoV-2 infected patients not discussed in the review is immune thrombocytopenia (ITP). Though ITP and consecutive bleeding has been particularly reported in association with SARS-CoV-2 vaccinations (Finsterer & Redzic, 2021), it has been also reported in patients with SARS-CoV-2 infections (Lévesque et al., 2020). Since platelet receptors bind various auto-antibodies, immune complexes, damage-associated molecular patterns (DAMPs), and complement factors, not only thrombus formation but also a propensity to bleeding may ensue from dysfunctional platelets (Sun et al., 2021). As circulating platelets also serve as a reservoir of immunomodulatory molecules, they play a role not only in the pathogenesis of autoimmune diseases, but can also predispose for thrombocytopenia and are thus linked to bleeding events (Sun et al., 2021). Another pathophysiological mechanism not considered are drugs that increase the propensity of bleeding as a side effect. In a recent report about a patient who was treated with bortezomib for COVID-19 intracerebral bleeding occurred (Finsterer & Scorza, 2021). A third pathophysiological mechanism to explain cerebral bleeding in SARS-CoV-2 infected patients is arterial hypertension. Since SARS-CoV-2 infections can be complicated by autonomic dysfunction and autonomic dysfunction may be associated with arterial hypertension, it is conceivable that newly developing arterial hypertension during a SARS-CoV-2 infection may be complicated by ICH if not treated adequately in due time. The review also lacks any discussion about endothelialitis as a cause of vessel rupture and thus micro- or macro-bleeding. In an autopsy study of patients dying through COVID-19, 56 patients had perivascular petechial haemorrhages (Bugra et al., 2021). In a recent study by means of high-resolution vessel wall MRI imaging (high-resolution vascular black blood sequences) it has been found that the majority of patients with COVID-19 associated encephalopathy had a circular enhancement and thickening of the basilar and vertebral arteries (Uginet et al., 2021). However, no correlation with ischemia or bleedings, reported in 21% and 59% of patients respectively, was found (Uginet et al., 2021). A type of cerebral bleeding not discussed in the review is micro-bleeding. Microbleeds have been reported in association with SARS-CoV-2 associated leuco-encephalopathy (Witvoet et al., 2021). Cerebral microbleeds have been also reported in association with critical ill disease (Edlow et al., 2021) and with extra-corporal membrane oxygenation (ECMO) therapy (Topiwala et al., 2021). Overall, the elegant study has some limitations which challenge the results and their interpretation. These limitations should be addressed to further strengthen the conclusions. The etiological spectrum of ICH in COVID-19 patients is much broader than usually anticipated.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. We declare that we do not have any commercial or associative interest that represents a conflict of interest in connection with the work submitted.

Ethical statement and patient’s consent

Informed consent was waived because of the retrospective nature of this study, which was approved by the Institutional Review Board of the Universidade Federal de São Paulo.

Consent for publication

All the authors have consented for publication of this manuscript.
  10 in total

1.  Reader Response: Critical Illness-Associated Cerebral Microbleeds in COVID-19 Acute Respiratory Distress Syndrome.

Authors:  Brian L Edlow; John Conklin; Susie Y Huang
Journal:  Neurology       Date:  2021-08-03       Impact factor: 9.910

2.  Patterns and Predictors of Extra-Corporeal Membrane Oxygenation Related Cerebral Microbleeds.

Authors:  Karan Topiwala; Haitham Hussein; Kamran Masood; Andrew Zhang; Bhavani Kashyap; Jason Bartos; Huseyin Tore; Eva Mistry; Bentho Oladi; Bharathi Jagadeesan; Mustapha Ezzeddine; Tapan Mehta
Journal:  J Stroke Cerebrovasc Dis       Date:  2021-10-23       Impact factor: 2.136

3.  Cerebrovascular Complications and Vessel Wall Imaging in COVID-19 Encephalopathy-A Pilot Study.

Authors:  Marjolaine Uginet; Gautier Breville; Jérémy Hofmeister; Paolo Machi; Patrice H Lalive; Andrea Rosi; Aikaterini Fitsiori; Maria Isabel Vargas; Frederic Assal; Gilles Allali; Karl-Olof Lovblad
Journal:  Clin Neuroradiol       Date:  2021-03-26       Impact factor: 3.649

4.  Postmortem pathological changes in extrapulmonary organs in SARS-CoV-2 rt-PCR-positive cases: a single-center experience.

Authors:  Aytul Bugra; Taner Das; Murat Nihat Arslan; Nihan Ziyade; Yalcın Buyuk
Journal:  Ir J Med Sci       Date:  2021-05-07       Impact factor: 1.568

5.  Severe immune thrombocytopenic purpura in critical COVID-19.

Authors:  Valérie Lévesque; Émilie Millaire; Daniel Corsilli; Benjamin Rioux-Massé; François-Martin Carrier
Journal:  Int J Hematol       Date:  2020-07-01       Impact factor: 2.490

6.  Symptomatic peduncular, cavernous bleeding following SARS-CoV-2 vaccination induced immune thrombocytopenia.

Authors:  Josef Finsterer; Zinka Redzic
Journal:  Brain Hemorrhages       Date:  2021-09-16

Review 7.  The relationship between COVID-19 infection and intracranial hemorrhage: A systematic review.

Authors:  Samuel R Daly; Anthony V Nguyen; Yilu Zhang; Dongxia Feng; Jason H Huang
Journal:  Brain Hemorrhages       Date:  2021-11-11

Review 8.  Platelet Activation Mechanisms and Consequences of Immune Thrombocytopenia.

Authors:  Siyu Sun; Rolf T Urbanus; Hugo Ten Cate; Philip G de Groot; Bas de Laat; Johan W M Heemskerk; Mark Roest
Journal:  Cells       Date:  2021-12-01       Impact factor: 6.600

9.  Intracerebral bleeding after Janus-kinase inhibitor baricitinib for COVID-19.

Authors:  Josef Finsterer; Fulvio A Scorza
Journal:  Brain Hemorrhages       Date:  2021-07-05
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.